Novartis gains global rights to Legend’s CAR-T cell therapies in deal worth over $1bn
15 Nov 2023
ImmunotherapyLicense out/inCell TherapyAcquisitionClinical Study
Preview
Source: PMLiVE
Novartis has entered into an exclusive licence agreement with Legend Biotech for global rights to a selection of CAR-T cell therapies targeting DLL3, with the deal potentially worth over $1bn.
Under the terms of the agreement, Novartis will gain exclusive worldwide rights to develop, manufacture and commercialise these cell therapies, which include an autologous CAR-T cell therapy candidate (LB2102) that Legend is taking into early-stage clinical development for extensive stage small cell lung cancer and large cell neuroendocrine carcinoma.
The deal also allows Novartis to apply its T-Charge cell therapy platform to the manufacturing process of these therapies, with LB2102 set to be the company's first application of T-Charge to a cell therapy candidate targeting solid tumours.
In exchange, Legend will receive a $100m upfront payment from Novartis and will be eligible to receive up to $1.01bn in clinical, regulatory and commercial milestone payments and tiered royalties.
“We believe LB2102 has an innovative CAR design and armour mechanism that increases its anti-tumour activity,” said Guowei Fang, chief scientific officer and head of business development at Legend Biotech. “The preclinical evidence shows that an autologous CAR-T could be a differentiated treatment option for patients with small cell lung cancer.”
Fang added that the combination of LB2102 with Novartis’ T-Charge platform “may potentially offer transformative benefits to small cell lung cancer patients”.
The Novartis/Legend agreement is just one of a series of deals that Novartis has made this year. In July, the company announced its acquisition of DTx Pharma, a preclinical stage biotech focused on developing siRNA therapies for neuroscience indications, in a transaction worth up to $1bn.
The merger included DTxDTx’s fatty acid ligand-conjugated oligonucleotide platform as well as its lead preclinical therapy for Charcot-Marie-Tooth disease, a slow-progressing and degenerative disease of the peripheral nervous system.
The month prior, the Swiss drugmaker also entered into an agreement to acquire Chinook Therapeutics for approximately $3.5bn, marking a notable expansion of its renal pipeline.
The deal granted Novartis access to the US biopharma’s two late-stage candidates in development for immunoglobulin A nephropathy, a rare and progressive kidney disease that mostly affects young adults.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.